,28 Both anti-IgE and anti-IL5/IL5R treatment demonstrated significant reductions in exacerbations in patients with severe asthma,10 possibly preventing elevated CV risks after exacerbations and avoiding the need for OCS bursts. The gene discussed is IL5RA; the disease is asthma.